By Dr. Benjamin Caplan, MD | Board-Certified Family Physician, CMO at CED Clinic | Evidence Watch
When Florida legalized smokable medical cannabis flower in 2019, the estimated amount of THC dispensed per patient rose by 10 to 42 percent and continued climbing over the following months. This interrupted time series study quantifies the dispensing shift at a population level, though it cannot determine actual patient consumption, health outcomes, or whether higher dispensing is inherently harmful.
Florida’s Smokable Cannabis Law Was Tied to a Sharp Rise in THC Dispensed Per Patient
A quasi-experimental interrupted time series analysis of Florida’s medical cannabis program finds that after smokable flower became legally available in 2019, the estimated weekly THC dispensed per certified patient jumped significantly and continued to rise across the 35-week follow-up period, with the magnitude of the increase depending heavily on assumed THC concentrations in flower products.
#72
Strong Clinical Relevance
Florida’s medical cannabis program is one of the nation’s largest, and this study provides rare quantitative evidence on how product-form policy changes reshape THC exposure at scale.
THC Dosing
Smokable Cannabis
Interrupted Time Series
Florida SB182
Florida operates one of the largest medical cannabis programs in the United States, with over 300,000 certified patients by early 2020. When state law expands product categories available for dispensing, the downstream effects on patient THC exposure are largely unknown because few jurisdictions systematically track and publish this data. Understanding whether policy changes meaningfully alter population-level dispensing patterns is essential for regulators, clinicians, and patients alike, especially as debates over daily dosing limits, product potency caps, and public health surveillance continue across dozens of state programs.
Before March 2019, Florida’s medical cannabis program restricted patients to non-smokable forms such as oils, capsules, and vaporizable concentrates. Senate Bill 182, signed into law in March 2019, removed this restriction and allowed dispensaries to sell smokable cannabis flower. The clinical and regulatory question at the heart of this study is straightforward: did the availability of a new product form, one that is widely recognized as the most popular mode of cannabis consumption, increase the total amount of THC moving through the state program on a per-patient basis? The authors used aggregate weekly dispensing reports published by the Florida Department of Health, combined with THC concentration estimates drawn from other state programs (since Florida does not publicly report product-level THC data), to model the per-patient THC dispensing trajectory before and after the policy took effect.
Under the primary assumption of 20% THC concentration in flower, the authors found a statistically significant immediate level increase of approximately 138 mg of THC per patient per week (a 42% jump) and a persistent upward trend of roughly 5.6 mg per patient per week across the 35-week post-phase-in period. Under the more conservative 10% THC assumption, the level increase was approximately 35 mg per patient per week (about 11%), with a smaller but still significant trend increase. The authors note that the post-policy dispensing level, if converted to an inhaled bioavailability equivalent using a 2:1 ratio relative to oral dosing, appears to substantially exceed expert-recommended daily THC doses. However, they acknowledge that this comparison is an extrapolation, that actual patient consumption is unknown, and that the study design cannot attribute any clinical outcomes to these dispensing shifts. They call for patient-level data linkage and outcome studies to determine whether these patterns translate into measurable health effects.
This study asks an important question: does expanding product options in a medical cannabis program change how much THC patients are accessing? The answer here is a reasonable yes, at least directionally. But I want to be careful about what this actually tells us. Dispensed THC is not consumed THC. It is certainly not therapeutic effect, nor is it harm. Many of my patients purchase more than they consume in a given week, and the onset of smokable availability likely attracted new enrollees with different baseline consumption patterns. The gap between aggregate dispensing data and individual clinical reality is enormous, and this study cannot bridge it.
In my practice, I see patients who do well with very small amounts of inhaled cannabis and others who require substantially more to manage chronic pain, nausea, or spasticity. What matters clinically is not whether a population-level metric exceeds an oral-dosing benchmark from a different context; what matters is whether the individual patient is achieving their therapeutic goals safely. I use this kind of research as a prompt to have frank dosing conversations, not as a reason to restrict product access. The real need is for better patient-level data and clinical outcome tracking, not for alarm about dispensing totals.
This study sits at the intersection of health policy evaluation and cannabis pharmacoepidemiology. For clinicians overseeing medical cannabis certifications, the finding that smokable flower availability was associated with higher per-patient THC dispensing is not surprising, but having it quantified in a peer-reviewed framework is useful. It supports the clinical intuition that product form availability shapes consumption patterns and underscores the need for practitioners to revisit dosing conversations with patients when new product categories become accessible. The study also illustrates how limited publicly available data remains in most state programs, which continues to hinder evidence-based clinical guidance.
Pharmacologically, inhaled cannabis flower has a rapid onset of action and a different bioavailability profile from oral preparations, which makes direct milligram-to-milligram comparisons between routes unreliable without patient-level titration data. The 2:1 bioavailability ratio cited in this study is a rough heuristic, not an established pharmacokinetic constant. Clinicians should be cautious about using this study to justify potency caps or dispensing limits without outcome data to support such measures. The most actionable takeaway is to proactively counsel patients about self-titration when they add or switch to
Have thoughts on this? Share it:
